Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News BD and Euroclone to develop new tests for sexually-transmitted diseases

BD and Euroclone to develop new tests for sexually-transmitted diseases

25th September 2017

BD has announced a new development partnership with Euroclone in the field of sexually-transmitted infections.

The companies will work together to create molecular tests to detect emerging sexually-transmitted pathogens, increasing the likelihood of patients receiving proper diagnoses and therapy whether or not they are exhibiting symptoms.

Additionally, the assays will support clinical laboratories in antimicrobial stewardship efforts and assist institutions in complying with European screening guidelines, allowing hard-to-detect genital mycoplasmas, including Mycoplasma and Ureaplasma species, to be identified more easily.

The tests will be the latest additions to the BD Max portfolio, which also includes BD SurePath, a liquid-based Pap test, and the BD Onclarity assay for the detection of 14 high-risk human papillomavirus genotypes.

Doug White, vice-president of women's health and molecular diagnostics for BD, said: "BD and Euroclone share a passion for reducing the risks associated with undiagnosed STIs, as well as the burden of symptoms that impact the lives of many worldwide."

BD and Euroclone plan to commercialise the assays outside of the US beginning in 2018 and in the US at a later date.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.